AV Laboratories unveils molecular skin care for GLP-1 users

AV Laboratories has released its 360° topical molecular nourishment approach to skin care to address cosmetic needs coming from the widespread use of GLP-1 medications. The science-led skin care brand aims to provide solutions that support the skin as it copes with sudden weight loss caused by GLP-1 drugs.

The company states that the cosmetics industry, especially skin care, must adapt to the metabolic and aesthetic impacts of the GLP-1 era to support the visible health and quality of skin during GLP-1 induced weight loss.

“Rapid physical change can place new demands on the skin’s appearance, and new demands require a more intelligent skin care approach,” says Sylwia Pawlaczyk, chief operating officer and master formulator at AV Laboratories. “AVL SOM3 was developed to help support the skin’s natural renewal environment with molecular building blocks associated with healthier-looking skin over time.”

The skin care system is powered by AV Laboratories’ patented AVL SOM3 technology and is touted to create “hydrated, resilient, younger-looking skin.”

Nourishing molecules through skin care

AV Laboratories’ AVL SOM3 longevity skin care technology was designed to bolster skin through nourishment on the molecular level through 20 amino acids. The ingredients encourage the skin to naturally support collagen, elastin, and NAD+ (nicotinamide adenine dinucleotide). The company’s foundation is in IVF solutions and stem cell research.

“Our work in IVF taught us how profoundly cellular health, precision, and care matter,” says CEO and co-founder Ami Mezezi.

AV Laboratories targets GLP-1 skin changes with molecular care.

“With AV Laboratories, we are bringing that same philosophy into skin care. As GLP-1s reshape how people think about metabolic health and longevity, skin deserves the same level of intelligent support, precision, and nourishment.”

The formulations pair AVL SOM3 with clinical-grade actives, taking a holistic approach to skin care. The brand aims to address a select few key pillars associated with common skin care concerns: structure, elasticity, hydration, barrier resilience, and the appearance of cellular energy.

“As more patients experience meaningful weight loss and metabolic change, the conversation naturally expands to how they feel in their skin,” says Dr. Olena Ivchenko, scientific advisory board member at AV Laboratories. 

“In aesthetic and longevity medicine, we look at the full picture: nutrition, hormones, lifestyle, medical care, and skin quality. Topical skin nourishment can be an important part of helping patients maintain a healthy-looking, resilient, radiant appearance throughout their transformation.”

With GLP-1 medications permeating medicine, cosmetics, and consumer demands, AL Laboratories states that 360° molecular nourishment is setting future-forward skin care standards.

GLP-1s and skin

AV Laboratories showcased its approach at the Aesthetic & Anti-Aging Medicine World Congress 2026 in Monaco. The approach arrives amid conversations on aesthetic medicine, metabolic health, long-term wellness, and GLP-1 drugs.

The brand is following growing discussions on the effects of metabolic changes and facial fat loss on skin integrity. It boasts a personal care industry edge due to its expertise in regenerative medicine and cellular science.

In addition to fat loss, the brand emphasizes that biological factors such as adipose tissue dynamics, dermal white adipose tissue, fibroblast signaling, collagen metabolism, hormonalOzempic face drives demand for clinical anti-aging solutions. balance, cellular energy, and nutrient availability can impact skin quality.

Furthermore, GLP-1 medications can cause appetite suppression, leading to insufficient nutritional intake. According to AV Laboratories, poor protein intake can have an especially detrimental effect on skin hydration, texture, and firmness as collagen and elastin rely on amino acids as building blocks.

Tackling Ozempic face

AV Laboratories is not the only company that has caught onto GLP-1-induced demands. Solutions to “Ozempic face” — the premature, sudden-onset skin laxity caused by GLP-1 use — continue to gain traction across the personal care industry.

Earlier this year, Debut launched an active ingredient, DermCeutical Elastin Deep Lift, targeting cellular aging, to address the demand for procedure-like results at home and help fight the skin effects of GLP-1 drugs.

“This isn’t a gradual, age-related change, but rather an unexpected side effect of these weight loss medications. As a result, skin laxity has become a growing concern across the population, accelerating demand for solutions that help restore dermal structural support,” Joshua Britton, PhD, founder and CEO at Debut, told Personal Care Insights.

At In-cosmetics Global 2026, Hagen Döring, area sales manager at Provital, told us about the launch of Intensilk, an ingredient designed for body care longevity in response to GLP-1 use-related consumer demands.